Gossamer bio will end the extension of a phase 2 study for a small molecule ulcerative colitis med that was found to be ineffective—the second time in 18 months the company has seen a top program fail a midstage trial.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,